Intellectual property strategy for regenerative medicine: is it time to 'regenerate'?
Takeshi S
TS
Komatani
D035843:Biomedical Research / Q000331:legislation & jurisprudence*; D005060:Europe; D033161:Government Regulation; D018973:Intellectual Property; D010330:Patents as Topic; D044968:Regenerative Medicine / Q000331:legislation & jurisprudence / Q000458:organization & administration; D014481:United States
Mayo; cellular medicine; data/market exclusivity; induced pluripotent stem cell (iPSC); intellectual property; market approval; myriad; natural products; ordre public (public order); patent; patent eligibility; priority; regenerative medicine; stem cell